en·fu·vir·tide

(ĕn-fyo͞o′vîr-tīd′)

An antiretroviral drug of the fusion inhibitor class used in combination with other drugs to treat HIV infection.

[en(try/)fu(sion inhibitor) + -vir, antiviral suff. (ultimately from virus) + (pep)tide.]

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

Translations

enfuvirtide

n enfuvirtida

References in periodicals archive

The following antiretroviral medications do not have any CYP-related interactions and therefore are not included in the Tables: abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil, zidovudine, enfuvirtide, maraviroc, and raltegravir.

Treating psychosis in patients with HIV/AIDS

T20 peptide (Enfuvirtide) is the first HIV entry inhibitor approved by United States Food and Drug Administration (U.

Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?

Dogan, "Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration," Amyloid, vol.

Localized Subcutaneous Insulin-Derived Amyloidosis Excised after Evaluation Using Ultrasonography in a Patient with Type 2 Diabetes Mellitus

Only one fusion inhibitor medication is available: enfuvirtide (Fuzeon[R]), also known as T-20 (AIDSinfo, 2016a; FDA, 2016).

Antiviral Medications, Part 2: HIV Antiretroviral Therapy

There are some drugs which may lead to ISRs in human like HIV-1 fusion inhibitor enfuvirtide, interferons, anti-TNF drugs adalimumab and etanercept.

Subcutaneous Toxicity of Agmatine in Rats/Sicanlarda Subkutan Agmatin Toksisitesi

Enfuvirtide and raltegravir scored 0 if used prior or during the genotyping test and 1 if they were never used.

Trends and predictors of HIV-1 acquired drug resistance in Minas Gerais, Brazil: 2002-2012

For example, in HIV infection this has been accomplished with the interference of virus entry using a gp41 protein derived peptide, enfuvirtide, which prevents fusion of the virus with the host cellular membrane [47].

Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro

A recent analysis of extensively treatment experienced, predominantly male, subjects switching enfuvirtide to RAL in France reported significant 24week decreases in interleukin-6, D-dimer, and hsCRP [46] that were not observed in these less treatment-experienced women with central adiposity [45].

Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial